The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

The repertoire of monoclonal antibodies and other biologic therapies targeted at precise
components of the immune response continues to expand rapidly. In theory, these therapies …

Biologics are increasingly becoming part of routine disease management. As more agents
are developed, the challenge of keeping track of indications and side effects is growing …

The advent of the antibiotic era ushered in a shift towards non-pathogen-specific therapy of
infectious diseases. This led to an overt emphasis on targeting microbial pathogens while …

Immunomodulatory biologics, which render their therapeutic effects by modulating or
harnessing immune responses, have proven their therapeutic utility in several complex …

The development of biologic therapies targeting proinflammatory mediators has led to
significant advances in the treatment of immune-mediated inflammatory diseases (IMIDs) …

Immunotherapies are disease management strategies that target or manipulate components
of the immune system. Infectious diseases pose a significant threat to human health as …

The advances in cancer biology and pathogenesis during the past two decades, have
resulted in immunotherapeutic strategies that have revolutionized the treatment of …

In the last decades of the 20th century, infectious diseases have re-emerged as a significant
public health problem in the developed world. However, the available anti-infective …

Microorganisms responsible for the infectious complications associated with anticytokine
therapy are generally intracellular pathogens or pathogens that commonly exist in a chronic …